Multiple Sclerosis Journal - October 2017 - 1450

Multiple Sclerosis Journal 23(11)
disability in multiple sclerosis. Neurology 2011;
76(14): 1206-1213.
49. Bergman J, Dring A, Zetterberg H, et al.
Neurofilament light in CSF and serum is a sensitive
marker for axonal white matter injury in MS. Neurol
Neuroimmunol Neuroinflamm 2016; 3(5): e271.

62. Eikelenboom MJ, Petzold A, Lazeron RHC, et al.
Multiple sclerosis: Neurofilament light chain
antibodies are correlated to cerebral atrophy.
Neurology 2003; 60(2): 219-223.

50. Kuhle J, Barro C, Disanto G, et al. Serum
neurofilament light chain in early relapsing remitting
MS is increased and correlates with CSF levels and
with MRI measures of disease severity. Mult Scler
2016; 22(12): 1550-1559.

63. Fabriek BO, Zwemmer JNP, Teunissen CE, et al.
In vivo detection of myelin proteins in cervical
lymph nodes of MS patients using ultrasound-guided
fine-needle aspiration cytology. J Neuroimmunol
2005; 161(1-2): 190-194.

51. Disanto G, Adiutori R, Dobson R, et al. Serum
neurofilament light chain levels are increased in
patients with a clinically isolated syndrome. J Neurol
Neurosurg Psychiatry 2016; 87(2): 126-129.

64. Bartos A, Fialová L, Soukupová J, et al. Elevated
intrathecal antibodies against the medium
neurofilament subunit in multiple sclerosis. J Neurol
2007; 254(1): 20-25.

52. Lycke JN, Karlsson JE, Andersen O, et al.
Neurofilament protein in cerebrospinal fluid: A
potential marker of activity in multiple sclerosis. J
Neurol Neurosurg Psychiatry 1998; 64(3): 402-404.

65. Petzold A, Eikelenboom MJ, Keir G, et al. Axonal
damage accumulates in the progressive phase of
multiple sclerosis: Three year follow up study. J
Neurol Neurosurg Psychiatry 2005; 76(2): 206-211.

53. Lu C-H, Petzold A, Topping J, et al. Plasma
neurofilament heavy chain levels and disease
progression in amyotrophic lateral sclerosis: Insights
from a longitudinal study. J Neurol Neurosurg
Psychiatry 2015; 86(5): 565-573.

66. Silber E, Semra YK, Gregson NA, et al. Patients
with progressive multiple sclerosis have elevated
antibodies to neurofilament subunit. Neurology 2002;
58(9): 1372-1381.

54. Rosengren LE, Karlsson JE, Sjögren M, et al.
Neurofilament protein levels in CSF are increased in
dementia. Neurology 1999; 52(5): 1090-1093.
55. Norgren N, Sundstrom P, Svenningsson A, et al.
Neurofilament and glial fibrillary acidic protein
in multiple sclerosis. Neurology 2004; 63(9):
1586-1590.
56. Dziedzic T, Metz I, Dallenga T, et al. Wallerian
degeneration: A major component of early axonal
pathology in multiple sclerosis. Brain Pathol 2010;
20(5): 976-985.
57. Petzold A. The prognostic value of CSF
neurofilaments in multiple sclerosis at 15-year
follow-up. J Neurol Neurosurg Psychiatry 2015;
86(12): 1388-1390.
58. Petzold A, Steenwijk MD, Eikelenboom JM, et al.
Elevated CSF neurofilament proteins predict brain
atrophy: A 15-year follow-up study. Mult Scler 2016;
22(9): 1154-1162.
59. Salzer J, Svenningsson A and Sundström P.
Neurofilament light as a prognostic marker in
multiple sclerosis. Mult Scler 2010; 16(3):
287-292.
60. Novakova L, Axelsson M, Khademi M, et al.
Cerebrospinal fluid biomarkers of inflammation and
degeneration as measures of fingolimod efficacy in
multiple sclerosis. Mult Scler 2017; 23: 62-71.
61. Kuhle J, Malmeström C, Axelsson M, et al.
Neurofilament light and heavy subunits compared

1450

as therapeutic biomarkers in multiple sclerosis. Acta
Neurol Scand 2013; 128(6): e33-e36.

67. Ehling R, Lutterotti A, Wanschitz J, et al. Increased
frequencies of serum antibodies to neurofilament light
in patients with primary chronic progressive multiple
sclerosis. Mult Scler 2004; 10(6): 601-606.
68. Fialová L, Bartos A, Svarcová J, et al. Serum
and cerebrospinal fluid light neurofilaments and
antibodies against them in clinically isolated
syndrome and multiple sclerosis. J Neuroimmunol
2013; 262(1-2): 113-120.
69. Amor S, van der Star BJ, Bosca I, et al.
Neurofilament light antibodies in serum reflect
response to natalizumab treatment in multiple
sclerosis. Mult Scler 2014; 20(10): 1355-1362.
70. Johnson GVW and Bailey CDC. Tau, where are we
now? J Alzheimers Dis 2002; 4(5): 375-398.
71. Teunissen CE, Dijkstra C and Polman C. Biological
markers in CSF and blood for axonal degeneration in
multiple sclerosis. Lancet Neurol 2005; 4(1): 32-41.
72. Kapaki E, Paraskevas GP, Michalopoulou M, et al.
Increased cerebrospinal fluid tau protein in multiple
sclerosis. Eur Neurol 2000; 43(4): 228-232.
73. Avsar T, Korkmaz D, Tütüncü M, et al. Protein
biomarkers for multiple sclerosis: Semi-quantitative
analysis of cerebrospinal fluid candidate protein
biomarkers in different forms of multiple sclerosis.
Mult Scler 2012; 18(8): 1081-1091.
74. Mitosek-Szewczyk K, Gordon-Krajcer W, Flis
D, et al. Some markers of neuronal damage in
cerebrospinal fluid of multiple sclerosis patients in
relapse. Folia Neuropathol 2011; 49(3): 191-196.

journals.sagepub.com/home/msj
https://journals.sagepub.com/home/msj
Table of Contents for the Digital Edition of Multiple Sclerosis Journal - October 2017
